Is AbbVie Inc (ABBV) overvalued? · P/E 81, rev $61.16B
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
This page asks whether AbbVie Inc (ABBV) looks expensive on cached numbers — not a short thesis.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ABBV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ABBV stock page for the full model, not this heading.
Not investment advice.